Ateroz

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ateroz

Quick Facts

Property Description
Active Ingredient Atorvastatin calcium trihydrate
Form Film-coated tablets
Pharmacological Class Statin (HMG-CoA reductase inhibitor)
Common Purpose To lower high concentrations of blood fats (lipids)
Origin Synthetic

What Type of Medicine is Ateroz?

Ateroz is a prescription-only medicine whose active substance is Atorvastatin, primarily used to manage blood lipid levels. It is classified as an antihyperlipidemic agent and belongs to the highly effective class of pharmaceuticals known as statins. This classification confirms that Atorvastatin is a key therapy for patients needing to manage their cholesterol and fat levels, supported by extensive clinical recognition for lipid modification.

The drug’s classification indicates its systemic purpose is to help control abnormally high concentrations of cholesterol and other fats in the bloodstream, specifically by reducing atherogenic lipoproteins. As an established, evidence-based therapy, Atorvastatin is utilized as a foundational agent for individuals who require significant modification of their lipid profile, often as a preventative measure for adults at risk of cardiovascular complications.

Atorvastatin: The Core Composition and Form

The core component of Ateroz is Atorvastatin calcium trihydrate, a molecule confirmed to be synthetic in origin, meaning it is manufactured through a precise chemical synthesis process. Ateroz is consistently formulated as a single-ingredient product and is provided as a film-coated tablet intended for oral administration.

This specific oral formulation ensures that the active substance, a potent structural analog, is delivered reliably into the body's system, allowing for targeted action primarily in the liver. Statins like Atorvastatin are recognized for their role in reducing cardiovascular risk across various patient groups.

What is the General Purpose of This Statin?

The general purpose of this medicine is to lower high concentrations of blood fats by reducing the body’s internal production of cholesterol. This action is achieved by the competitive inhibition of the hepatic enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase).

By blocking the HMG-CoA reductase enzyme, Atorvastatin significantly limits the liver’s ability to synthesize cholesterol, resulting in a substantial reduction of low-density lipoprotein cholesterol (LDL-C), commonly known as "bad cholesterol." This controlled optimization of the lipid profile is the primary therapeutic outcome, contributing to the management of risks associated with hypercholesterolemia.

Regulatory References

  1. NIH, Atorvastatin - StatPearls

What side effects are possible with Ateroz?

Possible Side Effects and Safety Information

The safety profile for Ateroz (Atorvastatin) is formally classified in regulatory documents based on the frequency of observed adverse reactions, ranging from Common (ge 1/100 to < 1/10) to Very Rare (< 1/10,000). The most frequently classified reactions, which fall into the Common category, involve the nervous system (headache), gastrointestinal system (nausea, diarrhea, dyspepsia, flatulence), and musculoskeletal system (myalgia, joint swelling, arthralgia, pain in extremity).


Serious Adverse Reactions and Safety Constraints

The official label emphasizes rare but serious adverse reactions, primarily affecting the muscles and liver. These include Rhabdomyolysis, a severe muscle effect, and Hepatic Failure, which has been reported rarely. Use of the medicine is formally contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases, and for women who are pregnant or breastfeeding. The label mandates Creatine Kinase (CK) levels and liver enzyme testing before initiating therapy and during treatment as clinically appropriate.

Population and Duration-Related Safety

Regulatory information cites specific populations where the risk of myopathy or rhabdomyolysis may be increased, including older adults and individuals with pre-existing renal impairment. Furthermore, the label notes time-related patterns, such as the need to consider the risk of serious muscle effects when starting or increasing the dosage. Instances of cognitive impairment (e.g., memory loss) reported post-marketing are generally noted as reversible upon discontinuation.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for an overdose of Ateroz (Atorvastatin) establishes that no specific treatment or antidote is known for overdosage. Management is officially defined as administering symptomatic care and instituting supportive measures as clinically required by the patient’s condition.

The most severe documented outcomes relate to the potential for significant musculoskeletal and hepatic injury. Overdose carries a risk of life-threatening complications, including rhabdomyolysis—a severe muscle breakdown that can lead to secondary acute renal failure (kidney damage). Severe liver injury, including fatal or non-fatal hepatic failure, has been reported in rare cases.

Manifestations of severe overdose exposure may include unexplained muscle pain, tenderness, or weakness, particularly when accompanied by elevated Creatine Kinase (CK) levels. Other signs of potential injury involve elevated serum transaminases, jaundice, or dark-colored urine.

Urgent medical attention is required immediately if an overdose is suspected or if a patient experiences any of these severe signs. Regulatory documentation mandates that in the event of an overdose, a patient must call a doctor or Poison Control Center right away and go to the nearest emergency room for continuous medical monitoring and supportive care.

Therapeutic Uses of Ateroz

Ateroz (Atorvastatin) is primarily used for managing symptoms related to systemic imbalance associated with high levels of blood fats. This medicine is commonly used to help with managing conditions involving episodic or fluctuating manifestations of high blood fats, including primary hyperlipidemia, mixed dyslipidemia, and severe genetic disorders like familial hypercholesterolemia. Ateroz is applied in situations where patients experience significantly elevated levels of Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides.

A core benefit of Ateroz is considered relevant for contributing to primary and secondary risk reduction of major cardiovascular events. The medicine is applied in addressing risk factors associated with severe cardiovascular symptoms that interfere with daily functioning. It is applied when appropriate for adolescents and children (aged 10 years and older) who have severe, inherited forms of hypercholesterolemia, as well as for adults diagnosed with established high cardiovascular risk, including those with pre-existing coronary heart disease or Type 2 Diabetes Mellitus.

“Therapy may assist with reducing risk factors associated with cardiovascular symptoms that create noticeable physiological strain.”


Quick Fact: Relief for Symptoms related to systemic imbalance
Primary Indication: Management of significantly elevated LDL-C and Triglycerides in conditions like hyperlipidemia and familial hypercholesterolemia.
Benefit: Helps manage risk factors associated with cardiovascular symptoms that create noticeable physiological strain.

Regulatory References

  1. National Institutes of Health (NIH) MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Ateroz?

Eligibility for Ateroz (Atorvastatin) is defined by official regulatory criteria, focusing on age, reproductive status, and pre-existing medical conditions.


Contraindications and Restrictions

Eligibility Status Population / Condition
Absolutely Prohibited Active liver disease or unexplained, persistent elevations of serum transaminases (liver enzymes).
Absolutely Prohibited Women who are pregnant or breastfeeding (lactation).
Absolutely Prohibited Patients with known hypersensitivity to Atorvastatin.
Conditional Use Pediatric patients (10 to 17 years old) are approved only for treating Heterozygous Familial Hypercholesterolemia (HeFH).
Not Recommended Children under 10 years of age.
Required Restriction Women of childbearing potential must use effective contraception during treatment.

Approved Populations

Use is approved for adults who require management of high blood fat levels (hypercholesterolemia and mixed dyslipidemia), as well as those with established cardiovascular risk factors. Use is also established for geriatric patients (65 years and older) under standard labeled conditions. The safety and efficacy of the medicine are not established in pre-pubertal girls.

What should I know about interactions with other medicines?

This section describes the officially documented interaction patterns for Ateroz, strictly based on government regulatory labeling.

Ateroz has documented interactions primarily stemming from pharmacokinetic changes and additive pharmacodynamic risk. Co-administration with the hepatitis C combination Glecaprevir plus Pibrentasvir is formally contraindicated. Combinations with Cyclosporine or Tipranavir plus Ritonavir must be avoided due to the risk of greatly increased systemic exposure and muscle-related events.

Interaction Category Interacting Substances and Constraint
Increased Exposure Risk Strong CYP3A4 inhibitors (e.g., Clarithromycin, Itraconazole) and transport inhibitors (OATP1B1, P-gp) markedly increase Atorvastatin plasma concentrations.
Additive Muscle Risk Fibric Acid Derivatives, Colchicine, and high-dose Niacin (lipid-modifying doses) increase the additive risk of skeletal muscle effects (myopathy).
Timing Rules Rifampin requires simultaneous co-administration to prevent a variable reduction in Atorvastatin concentration.
Food/Substance Intake of Grapefruit Juice must be limited. Caution is also advised regarding consumption of substantial quantities of alcohol.

Additionally, regulatory documents state that Atorvastatin may increase the plasma levels of co-administered Oral Contraceptives and Digoxin. Atorvastatin plasma concentrations are markedly increased in the presence of hepatic impairment, a factor noted to affect the overall interaction profile.

Mechanism of Action

Ateroz (Atorvastatin) functions through a multi-faceted pharmacodynamic mechanism centered on metabolic and vascular regulation. The primary action involves competitive inhibition of HMG-CoA Reductase in the liver. This enzyme is the rate-limiting step in the Mevalonate pathway, which governs de novo cholesterol synthesis. The resultant depletion of intracellular cholesterol triggers a compensatory response: the up-regulation of Low-Density Lipoprotein (LDL) Receptors on the hepatocyte surface. These receptors enhance the binding and catabolic clearance of circulating LDL and VLDL remnants from the blood plasma, resulting in a systemic reduction in circulating atherogenic lipoproteins. Beyond this lipid mechanism, the drug exerts pleiotropic effects by influencing intracellular signaling cascades within the vascular endothelium. This action modulates the activity of pro-inflammatory and oxidative mediators, influencing cellular processes within the arterial tissue.

Dosage and Administration Information

Ateroz (atorvastatin) is an oral medication taken to help manage lipid levels. Proper use focuses on the correct route, dosing, frequency, and administration conditions.

Administration Scope

Category General Instruction
Route of Administration The drug is for Oral Administration as a tablet.
Timing in Relation to Meals Tablets may be taken with or without food and at any time of day.
Dosing Schedule & Range The dose is taken once daily (QD). The typical adult starting dose is 10 mg or 20 mg, with a maximum dose of 80 mg daily. Doses should be adjusted at intervals of 4 weeks or more.

Specific Use Protocols

Age-Group Rules:

  • Pediatric (10–17 years) with Heterozygous Familial Hypercholesterolemia (HeFH): The recommended starting dose is 10 mg once daily, with the dose range not to exceed 20 mg daily.
  • Renal Impairment: No dosage adjustment is required in patients with renal dysfunction.

Special Procedural Conditions:

  • Co-administered Drugs: The maximum daily dose of Ateroz is restricted when taken alongside certain antiviral medications (e.g., specific HIV protease inhibitors) to 20 mg or 40 mg, as specified in the prescribing information to minimize risk.
  • Missed Dose: If a dose is missed, do not take the missed dose and resume the next scheduled dose; avoid taking two doses at the same time.

These instructions define the standardized method for administering Ateroz. The single daily dose and flexible timing simplify adherence, while defined dose limitations for special populations ensure use remains within established safety parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ateroz

Evidence for Lowering High Blood Fats (Hyperlipidemia and Dyslipidemia)

Atorvastatin has been studied for use in individuals with primary hyperlipidemia (high cholesterol) and mixed dyslipidemia (high cholesterol and triglycerides). The research exploring this use includes numerous short-term and intermediate-term Randomized Controlled Trials (RCTs), as well as studies exploring different dose levels. These studies explored outcomes related to systemic or functional imbalance by measuring changes in specific blood lipid biomarkers.

Across these research settings, studies reported measurements showing changes in biomarkers like Low-Density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol. Researchers also documented patterns observed in Triglyceride levels. Many of these studies focused on changes over a short duration, such as 3 to 12 weeks. This means that the follow-up durations were limited, and the evidence provides limited insight into long-term health outcomes beyond the measured changes in these blood biomarkers.


Research Studies on Cardiovascular Events: Secondary Prevention

Research explored Atorvastatin in adults who already have established Coronary Heart Disease (CHD), monitoring clinical outcomes such as non-fatal heart attacks and strokes. For this area of study, the evidence includes several large-scale, multi-center, long-term RCTs. These large trials monitored the occurrence of outcomes describing episodic or acute changes, such as non-fatal heart attacks, strokes, and the need for heart-related procedures.

During the multi-year follow-up periods of these major trials, research described the occurrence rates of these Major Adverse Cardiovascular Events (MACE). Studies also documented measurements of all-cause mortality across the populations observed. Additionally, the full very long-term effects are not fully established beyond the typical six-to-seven-year duration of the original primary studies.


Evidence in Special Populations, Including Children

Research has been conducted specifically in pediatric patients (children aged eight years and older) who have Heterozygous Familial Hypercholesterolemia (HeFH). Studies for this condition primarily measured changes in surrogate lipid markers. Controlled trials in children reported how blood fat biomarkers evolved in the observed populations, and also documented that regular assessments of growth and sexual maturation were performed. Research describing patients with Homozygous Familial Hypercholesteremia (HoFH) is inherently constrained by the disease's rarity, meaning sample sizes were modest in those settings.

Key Studies & References

  1. Atorvastatin - StatPearls (for general pharmacological context)
  2. Atorvastatin Oral: MedlinePlus Drug Information (for primary indications and use context)
  3. Efficacy and safety of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia (Pediatric Evidence)
  4. Efficacy and safety of atorvastatin in an elderly cohort of the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA) (Primary Prevention Evidence)

Frequently Asked Questions (FAQ)

Common questions about Ateroz (FAQ)

Q: What is the main reason doctors prescribe Ateroz?

A: Regulatory documents state that Ateroz is officially approved to lower high levels of cholesterol and triglycerides (fats) in the blood. Additionally, it is prescribed to reduce the risk of major cardiovascular events, such as heart attack and stroke, in specific patient populations.

Q: Is Ateroz the same kind of medicine as [similar drug name]?

A: Ateroz contains the medicine atorvastatin, which belongs to a class of medicines known as HMG-CoA reductase inhibitors, commonly referred to as statins. Medicines in this class function similarly by targeting the process of cholesterol production in the liver.

Q: How quickly can a person generally expect Ateroz to start working?

A: Studies indicate that the initial therapeutic effects of Ateroz on blood markers can begin within 2 weeks of starting treatment. The maximum cholesterol-lowering response is generally achieved after 4 weeks and remains consistent with continued use.

Q: Are the common side effects of Ateroz usually mild?

A: The official product information classifies side effects such as headache, diarrhea, and myalgia (muscle aches) as common. These common reactions are generally expected to be mild and manageable. Rare but serious side effects, such as muscle damage (rhabdomyolysis) or liver problems, are clearly listed separately.

Q: Does Ateroz interact with common over-the-counter pain relievers?

A: Official reports suggest no formal interaction between atorvastatin and common over-the-counter pain relievers like acetaminophen or ibuprofen. It is generally understood that taking these medications within their recommended dose limits does not pose a known interaction risk.

Q: Can Ateroz cause sleep issues, like insomnia or drowsiness?

A: Sleep disturbances, including difficulty sleeping (insomnia), have been reported as possible side effects associated with the use of statin medicines. If sleep issues occur, they should be noted as part of a patient's overall health picture.

Q: What should be avoided while taking Ateroz?

A: Regulatory warnings advise avoiding or limiting certain substances due to interaction risks. These include specific strong medications, such as some HIV or Hepatitis C antivirals, and limiting consumption of large quantities of grapefruit juice and substantial quantities of alcohol.

Q: Is there a generic version of Ateroz available?

A: Yes, the active medicine in Ateroz is atorvastatin, which is widely available as a generic prescription drug.

Q: What is Ateroz used for other than its main approved condition?

A: Beyond treating high cholesterol (hyperlipidemia), Ateroz is indicated for use in reducing the risk of a primary heart attack or stroke. It is also approved for patients to decrease the likelihood of needing certain heart procedures.

Q: Is Ateroz considered a long-term treatment?

A: Official information indicates that Ateroz is typically prescribed for chronic (long-term) therapy. The therapeutic response that lowers blood lipids is expected to be maintained through continued use of the medicine.

Q: Are there any food or drink restrictions while using Ateroz?

A: Yes, there are specific food and drink restrictions. Regulatory documents advise limiting or avoiding consumption of large quantities (more than 1.2 liters daily) of grapefruit juice. Caution is also advised regarding the consumption of substantial quantities of alcohol.

Q: Why is Ateroz sometimes prescribed along with other medicines?

A: Ateroz may be prescribed alongside other medicines in order to help patients reach specific blood cholesterol or triglyceride goals. This approach aligns with established treatment guidelines for achieving target lipid levels.

Q: Do studies suggest Ateroz is an effective treatment?

A: Studies and official information indicate that Ateroz is effective in its approved uses. Clinical trials have shown that the medicine significantly reduces blood cholesterol markers (LDL-C) and lowers the occurrence rate of major cardiovascular events.

Q: How does Ateroz affect blood test results?

A: Ateroz affects the results of blood tests used to monitor treatment safety and effectiveness. These include tests measuring liver enzymes and creatine kinase (CK) levels, which are used to check for rare side effects. The medicine is also expected to change lipid biomarkers like LDL-C and triglycerides.

Q: Is Ateroz safe for older adults (the elderly)?

A: Yes, Ateroz is used in older adults, and regulatory documents include data for this population. However, being 65 years of age or older is listed as a potential risk factor for developing muscle-related side effects (myopathy), which may require careful monitoring.

Q: How long does Ateroz stay in the body after the last dose?

A: Pharmacokinetic data shows that the mean elimination half-life of atorvastatin is about 14 hours. However, the cholesterol-lowering activity lasts longer, typically 20 to 30 hours, due to the action of its active metabolites (breakdown products).

Q: Can a person take Ateroz if they have diabetes?

A: It is approved for use in certain patients, including those with type 2 diabetes, to reduce cardiovascular risk. The FDA has noted that statins may cause small increases in blood sugar (glucose) and HbA1c levels.

Q: Does Ateroz have any impact on mood or energy levels?

A: Adverse event reports associated with statin use have included the possibility of feeling general fatigue or experiencing mood-related disorders, such as depression. This information is captured in some regulatory documents.

Q: Are there different strengths of Ateroz available?

A: Yes, Ateroz (atorvastatin) is typically manufactured in multiple tablet strengths. The most common strengths available in the market are 10 mg, 20 mg, 40 mg, and 80 mg.

Q: What information should I provide to my healthcare provider before starting Ateroz?

A: Official patient information highlights the importance of discussing medical history before starting treatment. This includes any history of liver, kidney, or thyroid problems, diabetes, muscular disorders, or regular consumption of alcohol or supplements.

Q: What is the difference between Ateroz and a placebo in clinical trials?

A: Clinical studies found a significant difference in results between Ateroz and a placebo (an inactive treatment). Regulatory documents indicate that Ateroz significantly reduced important blood lipid levels, including LDL-C, Total Cholesterol, and triglycerides, when compared to the placebo.

Q: What are the signs of a serious allergic reaction to Ateroz?

A: Signs of a serious allergic reaction that require immediate medical attention include severe breathing or swallowing difficulties. This also includes any rapid swelling of the face, lips, tongue, or throat.

Q: Can I take vitamins or supplements while on Ateroz?

A: Interactions have been reported between atorvastatin and certain supplements, specifically St. John's wort and lipid-modifying doses of niacin. Official information emphasizes the importance of consulting a healthcare provider before combining Ateroz with any vitamins or supplements.

Q: What should I do if the side effects of Ateroz are bothersome?

A: Regulatory guidance indicates that one should contact a healthcare provider or pharmacist for common side effects that are bothersome or persistent. They can provide clinical advice on managing the symptoms or reviewing the treatment as appropriate.

Q: How does Ateroz affect kidney function?

A: A pre-existing kidney condition generally does not require a change in the dose of Ateroz. However, regulatory warnings note that severe muscle damage (rhabdomyolysis) is a rare adverse event that can potentially lead to acute kidney injury.

Q: Is Ateroz suitable for children and adolescents?

A: Ateroz is approved for use in children and adolescents aged 10 years and older who have been diagnosed with certain types of high cholesterol (Familial Hypercholesterolemia). The dosing and safety profile are specifically established for this population.

Q: Why are there warnings about grape juice and Ateroz?

A: The warning exists because grapefruit juice can interfere with the way the body processes atorvastatin, causing its blood levels to increase significantly. This increased exposure raises the risk of serious side effects, particularly muscle-related problems and liver damage.

Q: Are there different brand names for the medicine Ateroz?

A: Yes, Ateroz is one brand name. The medicine contained in Ateroz, atorvastatin, is also widely known and marketed under the brand name Lipitor.

Q: What happens if I take Ateroz with alcohol?

A: Official documents advise caution regarding the consumption of substantial quantities of alcohol. Regularly consuming alcohol may increase the risk of developing liver-related or muscle-related side effects while taking Ateroz.

Q: Is there a link between Ateroz and sun sensitivity?

A: While not a common adverse effect, there have been rare case reports documented that link atorvastatin use to phototoxicity, which is an increased sensitivity of the skin to sunlight.

Q: Does Ateroz have a risk of raising blood sugar?

A: The FDA has issued safety information noting that statin use is associated with a small, increased risk of elevated blood sugar. Increases in both fasting serum glucose and HbA1c levels have been reported.

Q: Is Ateroz only for a specific gender?

A: No, Ateroz is not limited to a specific gender. While plasma concentrations may be different between men and women, studies show the clinical effectiveness in lowering cholesterol is not significantly different. The only gender-specific constraints relate to use during pregnancy and breastfeeding.

How should Ateroz be stored and disposed of?

Storage Conditions for Ateroz (Atorvastatin) Tablets

Ateroz tablets must be stored at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F), with permitted brief temperature excursions up to 30 C. The medicine must be kept in the original container and maintained tightly closed to protect it from moisture, heat, and light.

Child Safety and Disposal

All medication must be kept securely out of the sight and reach of children to prevent accidental ingestion.

Expired or unused Ateroz must be handled according to strict regulatory guidelines. The product must not be thrown away with household waste or disposed of in wastewater. Instead, the disposal of the unused product must follow local pharmaceutical waste regulations, often requiring consultation with a pharmacist or using designated collection points.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ateroz found in:

A-Z Index: